Silvia Tenembaum

Professor, National Pediatric Hospital Dr. J. Garrahan

Dr Tenembaum received her medical degree with honors from the School of Medicine, University of Buenos Aires. This was followed by an extensive training in Pediatrics and Pediatric Neurology at the Hospital R. Gutiérrez, in Argentina. She is the founder and Director of the Pediatric Neuroimmunology Clinic and Program, and Senior Consultant of the Department of Neurology, Pediatric Hospital Dr Juan P. Garrahan, a tertiary referral pediatric hospital in Buenos Aires, Argentina.
She has had a longstanding interest in acquired neuroinflammatory disorders with pediatric onset and has established a Comprehensive Care Clinic for children with multiple sclerosis, neuromyelitis optica, ADEM, autoimmune encephalitis, and related disorders. Her work has contributed to the characterization and understanding of different pediatric CNS neuroinflammatory disorders through collaborative international networks and study groups. Dr Tenembaum is a founding member of the International Pediatric MS Study Group (IPMSSG), and past-Chair of its Steering and Nominating Committees. She has served as an active member of the NMO-Roundtable Study Group, Guthy Jackson Charitable Foundation, since 2009. She participated in the International Panel for the NMOSD Diagnostic Criteria 2015, and the International Panel for MOGAD Diagnostic Criteria 2023. She has also worked with the International Group for Optic Neuritis Diagnosis and Classification and participated with the group of experts generating the Consensus-based recommendations for the Treatment of pediatric NMDAR antibody encephalitis. She is currently working with the IPND for the Revised NMOSD Diagnostic Criteria 2025.
She serves as Editorial Board member of the following journals: Neurology: Neuroimmunology & Neuroinflammation, Frontiers in Neurology, and Neurology and Therapy. She also serves as an expert reviewer for many journals. Dr Tenembaum has authored numerous papers and chapters in national and international books. She has also been invited to chair or lecture at multiple expert meetings and international conferences.
Dr Tenembaum has been elected as an Executive Board Member of the International Child Neurology Association (ICNA) for three terms since 2014. She is currently participating in five pediatric clinical studies evaluating the impact of Satralizumab and Inebilizumab in children with AQP4-IgG positive NMOSD, comparing the efficacy and safety of Ofatumumab, Siponimod, Fingolimod, and Ocrelizumab in children and adolescents with MS, and the impact of Satralizumab in pediatric patients with NMDAR encephalitis.